ACCC rejects 'opt-out' clause
The ACCC announced on Friday it was proposing to grant conditional authorisation to edition 18 of Medicines Australia’s Code of Conduct for five years. The code sets the standards for the marketing and promotion of prescription pharmaceutical products in Australia by member companies.
In edition 18, Medicines Australia proposed a new reporting regime which required reporting of “transfers of value” – such as speaking fees, advisory board fees or sponsorship to attend a conference — subject to the healthcare professional’s consent.
The issue of individual disclosure has been a matter of debate for years.
When authorising edition 17 of the code in 2012, the ACCC said it had made clear to Medicines Australia that it should review transparency measures and introduce greater disclosure around sponsorship and fees paid to individual doctors.
“The ACCC supports the introduction by Medicines Australia of a